RecruitingNCT07317245

HUmanitas PROtontherapy (HU-PRO)


Sponsor

Istituto Clinico Humanitas

Enrollment

500 participants

Start Date

Jan 12, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Proton therapy is a cancer treatment, similar to the more commonly used radiation therapy. It uses radiation to destroy cancer cells and helps control the disease in the treated area. However, when proton therapy is compared with standard radiation therapy, many studies show fewer side effects and better disease control. This is due to the unique physical properties of the particles used in proton therapy. At present, in Italy, this innovative treatment is available only for selected diseases, as defined by national guidelines. For this reason, it is very important to collect as much data as possible to support the further development of proton therapy and to improve treatment safety and effectiveness.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Solid tumors candidate to proton therapy, in particular, according to Italian regolamentations
  • Written informed consent for HU-PRO according to applicable legal and ethical requirements
  • Indication for proton therapy
  • ≥ 18 years old
  • ECOG PS (performance status scale) 0-2

Exclusion Criteria4

  • Age < 18 years old
  • ECOG (performance status scale) >3
  • Life expectancy < 3 months
  • Inability to provide informed consent

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS Humanitas Research Hospital

Rozzano, Michigan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07317245


Related Trials